Hemophilia A Without Inhibitors clinical trials

Explore recruiting hemophilia a without inhibitors clinical trials.

Recruiting hemophilia a without inhibitors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hemophilia A Without Inhibitors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-Label Phase IV Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes, in Participants Aged ≥13 and < 70 Years with Severe or Moderate Hemophilia a Without FVIII Inhibitors on Emicizumab Prophylaxis

Italy, Spain, Hungary, Germany

Therapeutic use (Phase IV) EU CTIS Study details

A phase IIIb, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Patients From Birth to 12 Months of Age with Hemophilia A without Inhibitors

Italy, France, Belgium, Spain, Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS

France, Austria, Poland, Netherlands, Spain, Denmark +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients with Mild or Moderate Hemophilia A without FVIII Inhibitors

Germany, France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)

Spain, Germany, Belgium, Italy, France, Poland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Hemophilia A Without Inhibitors trials by city

Hemophilia A Without Inhibitors in Toronto Hemophilia A Without Inhibitors in Vancouver Hemophilia A Without Inhibitors in Montreal Hemophilia A Without Inhibitors in Calgary Hemophilia A Without Inhibitors in Edmonton Hemophilia A Without Inhibitors in Ottawa Hemophilia A Without Inhibitors in Winnipeg Hemophilia A Without Inhibitors in Quebec City Hemophilia A Without Inhibitors in Hamilton Hemophilia A Without Inhibitors in Kitchener Hemophilia A Without Inhibitors in London Hemophilia A Without Inhibitors in Halifax Hemophilia A Without Inhibitors in New York Hemophilia A Without Inhibitors in Los Angeles Hemophilia A Without Inhibitors in Chicago Hemophilia A Without Inhibitors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease